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2206United States (1). The occurrence
of AF is associated with increases
in both cardiovascular and all-
cause mortality (2,3). Catheter
ablation offers a viable alternative
in symptomatic patients who
are refractory to pharmacological
therapy (4,5), and the use of
catheter ablation is increasing (6).
The pulmonary veins are the key
targets for the ablation of AF (4).
For this reason, detailed anatomic
imaging of the left atrium and
pulmonary veins is routinely per-
formed before the performance of
catheter ablation (6,7). Imaging
is performed to allow the use
of advanced mapping systemsduring the procedure, to detect anatomical variants, and to
minimize complications (8). Multiple different techniques
exist for anatomical imaging, including angiography, com-
puted tomography (CT), ultrasound, and cardiac magnetic
resonance (CMR) imaging, and there are currently no
guidelines and limited clinical data to support an advantage
for one imaging modality over another (9). CMR imaging
provides accurate and detailed pulmonary vein anatomy
before pulmonary vein isolation (10), and CMR imaging
may also provide complementary information. Speciﬁcally,
left ventricular (LV) myocardial ﬁbrosis identiﬁed using
late gadolinium enhancement (LGE) has been shown to be
a predictor of adverse outcomes in broad groups of patients
(11–15). However, there are limited data on the presence,
pattern, and prognostic signiﬁcance of LV LGE in patients
with AF (16). Therefore, the aim of this study was to deter-
mine the incidence, pattern, and prognostic signiﬁcance of
unanticipated LV LGE in patients with AF. We hypothe-
sized that unanticipated LV LGE would be a frequent
occurrence and that the presence of LV LGE would be
associated with adverse outcomes.Methods
Study population. We prospectively collected data on all
consecutive patients from September 2005 through June
2011 who underwent CMR studies before pulmonary vein
isolation. The study indication was speciﬁcally for the
identiﬁcation of pulmonary vein anatomy (7). All patients at
our institution in whom pulmonary vein isolation is being
planned, and without contraindications to the performance
of a magnetic resonance study, undergo CMR imaging of
the pulmonary venous anatomy. Contraindications to
a CMR study included the presence of a permanent pace-
maker, severe claustrophobia, and severe impairment of renal
function (glomerular ﬁltration rate <30 ml/min/1.73 m2).
Paroxysmal AF was deﬁned as AF that terminated
spontaneously <7 days after onset, while persistent AF wasdeﬁned as that extending beyond 7 days. Hypertension was
deﬁned as systolic blood pressure >139 mm Hg or diastolic
blood pressure >89 mm Hg on multiple measurements or
the use of antihypertensive medication. Heart failure was
deﬁned as a clinical history of heart failure or reduced LV
ejection fraction (EF). We deﬁned recurrence of AF as
AF occurring >3 months after pulmonary vein isolation
and conﬁrmed by either electrocardiography (ECG) or
cardiac monitoring. We subsequently excluded patients
who had prior myocardial infarctions (MIs) by either
clinical evidence of MI per electronic medical records or
electrocardiographic evidence, deﬁned by Minnesota
codes 1.1.1 to 1.2.8 (17). We also obtained LV measure-
ments on echocardiography that was performed at the time of
the planned ablation. The Human Subjects Research Review
Committee of our institution approved the study protocol.
CMR protocol. All images were acquired with electrocar-
diographic gating, breath holding, and the patient in a supine
position. Subjects were imaged using either a 1.5-T or 3.0-T
CMR system (Signa HDxt, GE Healthcare, Waukesha,
Wisconsin, or Tim Trio, Siemens Healthcare, Erlangen,
Germany, respectively). The CMR protocol consisted of cine
steady-state free precession imaging for cardiac function
(typical repetition time 3.4 ms, echo time 1.2 ms, in-plane
spatial resolution 1.6  2 mm), pulmonary vein anatomy
imaging, and LGE imaging (repetition time 4.8 ms, echo
time 1.3 ms, inversion time 200 to 300 ms). For LGE
imaging, a segmented inversion-recovery pulse sequence was
used starting 10 to 15 min after a single bolus dose of 0.15
mmol/kg of gadolinium diethylenetriamine penta-acetic acid
(Magnevist, Bayer AG, Leverkusen, Germany). Cine
imaging and LV LGE imaging were performed in 8 to 14
matching short-axis (8 mm thick with 0-mm spacing) and 3
radial long-axis planes. This CMR prescription was to ensure
that whole-heart coverage was obtained for complete LV and
right ventricular assessment. LGE was interpreted as present
or absent by the consensus of 2 CMR-trained physicians.
LGEwas considered present only if conﬁrmed on both short-
axis and matching long-axis myocardial locations. LGE
extent was quantiﬁed using a semiautomatic detection
method using a previously validated research tool (Mass
Research, Leiden University Medical Center, Leiden, the
Netherlands), with the extent of LGE deﬁned using the full
width at half maximum criteria (18). The mass of LV LGE
was measured in grams and was expressed as a percent of the
total LV mass. The distribution of LGE was characterized as
subendocardial, transmural, midwall, epicardial, or focal/
involving the right ventricular insertion points.
Methods of clinical follow-up. The endpoint of interest
was all-cause mortality. We ascertained patient mortality
using the Social Security Death Index and reviewed the
electronic medical records of all patients. When a patient’s
electronic medical record provided insufﬁcient follow-up
information, the patient’s primary provider was contacted
regarding clinical events. Complete follow-up was available
for all patients.
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2207Statistical analysis. Continuous data are presented as
mean  SD. Continuous data were compared using an
unpaired Student t test or Mann-Whitney nonparametric
test as appropriate. Variables lacking normal distributions
and evaluated with nonparametric tests are summarized as
medians and quartiles. Nominal data are presented as
numbers and percents and were compared using Fisher
exact tests or a chi-square test, as appropriate. The hazard
ratio (HR) for the prediction of the event was calculated
for mortality using a Cox regression model using 3
cohorts: all patients, patients without evidence of MI by
clinical history or ECG, and patients without evidence ofTable 1
Characteristics of All Patients, Patients Without Prior MIs b
Absence of LGE
Variable
Entire Cohort
(n ¼ 720)
No Prior M
(n ¼ 664
Age (yrs) 56  10 56  11
Men 531 (74%) 484 (73%
Duration of AF 50 (29–83) 49 (29–8
Paroxysmal AF 250 (35%) 229 (35%
Persistent AF 472 (66%) 435 (65%
Prior AF ablation 173 (24%) 160 (24%
Cardiovascular risk factors
Diabetes mellitus 106 (15%) 98 (15%
Hypertension 365 (51%) 324 (49%
Heart failure 186 (26%) 172 (26%
Obstructive sleep apnea 142 (20%) 130 (20%
Valvular heart disease 77 (11%) 70 (11%
Hyperthyroidism 34 (5%) 32 (5%)
Hypercholesterolemia 240 (33%) 203 (31%
Excessive alcohol intake 59 (8%) 54 (8%)
Family history of AF 88 (12%) 84 (13%
Medications
Aspirin 325 (45%) 291 (44%
Beta-blockers 491 (68%) 446 (67%
Calcium-channel blocker 164 (23%) 148 (22%
ACE inhibitors/ARBs 261 (36%) 234 (35%
Class I antiarrhythmic agents 157 (22%) 157 (24%
Class III antiarrhythmic agents 341 (47%) 298 (45%
Digoxin 64 (9%) 56 (8%)
Spironolactone 19 (3%) 17 (3%)
Diuretic agents 126 (18%) 117 (18%
Statins 237 (33%) 188 (28%
BMI (kg/m2) 29  5 29.5 
Systolic blood pressure (mm Hg) 127  17 127  1
Diastolic blood pressure (mm Hg) 75  12 75  12
Heart rate (beats/min) 72  17 72  17
Electrocardiographic parameters
Sinus rhythm at presentation 459 (64%) 430 (65%
AV delay (ms) 172  31 172  3
QRS duration (ms) 96  15 96  15
QTc duration (ms) 442  33 441  3
LVH by ECG (Sokolov criteria) 56 (8%) 52 (8%)
GFR (ml/min/1.73 m2) 83  17 83  17
Values are mean  SD, n (%), or median (interquartile range). *LGE-positive versus LGE-negative patien
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin receptor blocker; AV
rate (using the Modiﬁcation of Diet in Renal Disease formula done at the time of cardiac magnetic
MI ¼ myocardial infarction; QTc ¼ corrected QT.MI by clinical history, ECG, or LGE imaging. We
considered all the signiﬁcant variables in the univariate
analysis and sought the best overall multivariate models
for mortality, by stepwise forward selection with a proba-
bility to enter the set at p ¼ 0.01 and to remove the effect
from the regression at p ¼ 0.01. Event curves were
determined according to the Kaplan-Meier method, and
comparisons of mortality rates were performed using the
log-rank test. A 2-tailed p value <0.05 was considered
signiﬁcant for all other analyses. SAS was used
for statistical analysis (SAS Institute Inc., Cary, North
Carolina).y Clinical History or ECG, and Stratiﬁed by the Presence or
I
)
LGE
(n ¼ 88)
No LGE
(n ¼ 576) p Value*
59  10 55  10 0.007
) 63 (71%) 421 (73%) 0.69
4) 54 (34–84) 49 (16–77) 0.71
) 32 (36%) 197 (34%) 0.72
) 49 (60%) 386 (67%) 0.72
) 24 (27%) 136 (24%) 0.50
) 18 (20%) 80 (14%) 0.11
) 50 (57%) 274 (48%) 0.11
) 32 (36%) 140 (24%) 0.02
) 27 (31%) 103 (18%) 0.009
) 12 (14%) 58 (10%) 0.35
5 (6%) 27 (5%) 0.60
) 31 (35%) 172 (30%) 0.32
5 (6%) 49 (8%) 0.53
) 10 (11%) 74 (13%) 0.73
) 39 (44%) 252 (44%) 0.95
) 66 (75%) 380 (66%) 0.11
) 19 (22%) 129 (22%) 1.00
) 34 (39%) 200 (35%) 0.47
) 16 (18%) 141 (24%) 0.22
) 45 (51%) 253 (44%) 0.21
8 (9%) 48 (8%) 0.38
3 (3%) 14 (2%) 0.48
) 20 (23%) 97 (17%) 0.18
) 30 (34%) 158 (27%) 0.21
5 30.6  5 29.2  5 0.03
7 126  19 127  17 0.89
74  12 75  12 0.56
73  19 72  17 0.88
) 56 (64%) 374 (65%) 0.81
2 185  33 170  31 0.006
100  18 95  14 0.006
3 445  28 440  33 0.15
8 (9%) 44 (8%) 0.67
78  17 84  17 0.001
ts without clinical histories of MI.
¼ atrioventricular; BMI ¼ body mass index; ECG ¼ electrocardiography; GFR ¼ glomerular ﬁltration
resonance imaging); LGE ¼ late gadolinium enhancement; LVH ¼ left ventricular hypertrophy;
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In total, 720 consecutive patients were referred for CMR
imaging in preparation for pulmonary vein isolation. Of the
entire cohort, 56 patients had prior MIs by clinical history or
ECG. Cohort characteristics from the entire cohort of
720 patients, the 664 patients without known MI by clinical
history or ECG, and this cohort of 664 patients further
stratiﬁed according to the presence or absence of LGE are
presented in Table 1. In brief, in this ﬁnal study cohort,
there were 484 men (73%), with a mean age of 56 11 years
(range: 24 to 85 years). Patients presented a median of
49 months after ﬁrst symptomatic onset of AF (range:
12 months to 12 years); 435 patients (65%) had persistent
AF, 229 (35%) had paroxysmal AF, and 430 (65%) were
in sinus rhythm at the time of the study. There were 324
patients (49%) with hypertension, 130 (20%) with sleep
apnea, 98 (15%) with diabetes, and 172 (26%) with heart
failure. In total, 429 patients (69%) were taking class I or
class III antiarrhythmic agents.
Imaging characteristics. Imaging characteristics from the
entire cohort of 720 patients, the 664 patients without
known MI by clinical history or ECG, and this cohort
separated according to the presence or absence of LGE
are presented in Table 2. By echocardiography, the meanTable 2
Imaging Characteristics of All Patients, Patients Without Pr
Presence or Absence of LGE
Variable
Entire Cohort
(n ¼ 720)
No Prior
(n ¼ 66
Echocardiographic parameters
LV EF (%) 55  10 55  1
LV diastolic dimension (mm) 49  5 49  5
Estimated PASP (mm Hg) 29  7 29  7
Left atrial dimension (mm) 41  6 41  6
CMR imaging
LV EDV (ml) 168  43 167  4
LV ESV (ml) 75  28 74  2
LV EF (%) 56  10 56  1
LV mass (g) 149  33 148  3
LV mass index (g/m2) 72  12 71  1
RV EDV (ml) 164  42 163  4
RV ESV (ml) 80  26 80  2
RV EF (%) 52  7 52  8
Left atrial dimension (mm) 41  7 41  7
LV LGE 108 (15%) 88 (13%
LV LGE FWHM (% of LV mass) 6.4  3.5 5.9  3
LV LGE location
Subendocardial 50 (46%)
Transmural 14 (13%)
Epicardial 1 (1%)
Midmyocardial 32 (30%)
Insertion points 11 (10%)
Values are mean  SD or n (%). *LGE-positive versus LGE-negative patients without clinical histories of
CMR ¼ cardiac magnetic resonance; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; ESV ¼ end-sy
systolic pressure; RV ¼ right ventricular; other abbreviations as in Table 1.LV EF was 55  10%, the mean LV end-diastolic di-
mension was 49  5 mm, the mean left atrial dimension was
41  7 mm, and the mean estimated pulmonary artery
systolic pressure was 29  7 mm Hg. By CMR imaging, the
mean LV end-diastolic volume was 167  42 mL, the mean
LV EF was 56  10%, the mean LV mass indexed to body
surface area was 71  12 g, the mean right ventricular end-
diastolic volume was 163  42 ml, and the mean right
ventricular EF was 52  8% (Table 2).
LGE. Among the entire cohort, LGE was detected in
108 patients (15%). Among the entire cohort, the LGE
pattern was ischemic in 59% (transmural in 14 [13%] and
subendocardial in 50 [46%]) and nonischemic in 41%
(midmyocardial in 32 [30%], insertion point in 11 [10%],
and epicardial in 1 [1%]) (Table 2). When patients with
clinical histories or electrocardiographic evidence of MI
were excluded, LGE was detected in 88 (13%) (Table 2).
The pattern of LGE was ischemic in 50% (transmural
in 6 [7%] and subendocardial in 38 [43%]) and nonischemic
in 50% (midmyocardial in 32 [37%], insertion point in
11 [12%], and epicardial in 1 [1%]; representative images
are displayed in Fig. 1). The mean extent of LGE was
5.9  3% (median 5.2%; range: 1.2% to 14.6%). Patients
were grouped according to the presence or absence of
LGE (Tables 1 and 2). There were baseline differencesior MIs by Clinical History or ECG, and Stratiﬁed by the
MI
4)
LGE
(n ¼ 88)
No LGE
(n ¼ 576) p Value
0 54  13 55  10 0.21
49  7 49  5 0.62
28  7 29  7 0.28
43  6 41  6 0.0004
2 165  42 167  42 0.68
7 76  30 73  26 0.37
0 54  12 57  9 0.006
3 154  37 148  33 0.08
2 74  14 71  12 0.01
2 154  43 164  42 0.07
6 75  29 81  25 0.10
53  8 52  7 0.32
44  8 40  7 <0.0001
)
38 (43%)
6 (7%)
1 (1%)
32 (37%)
11 (12%)
MI.
stolic volume; FWHM ¼ full width at half maximum; LV ¼ left ventricular; PASP ¼ pulmonary artery
Figure 1 Representative LGE Images
Late gadolinium enhancement (LGE) images comparing a normal patient (A); a patient with midmyocardial (LGE), typically seen in dilated cardiomyopathy (B); a patient with
a subendocardial MI (C); and a patient with subepicardial LGE (D). Regions of LGE are highlighted using white arrows.
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2209among the cohorts with and without LGE. Patients with
LGE were on average older and were more likely to have
heart failure and sleep apnea. Patients with LGE were also
more likely to have lower glomerular ﬁltration rates, lower
LV EFs, increased LV mass, increased left atrial dimen-
sions, longer PR intervals, and wider QRS intervals. We
performed clinical follow-up in patients with unanticipated
LGE. There were 44 patients with LGE in an ischemic
distribution. Of these 44 patients, 42 underwent stress
testing with imaging, 26 had evidence of ischemia, 21 had
evidence of signiﬁcant coronary artery disease on angiog-
raphy, and 18 underwent revascularization procedures. Of
the patients with LGE in a nonischemic distribution
(n ¼ 44), 38 underwent stress testing or angiography.
Of these patients, 5 had evidence of signiﬁcant coronary
artery disease, and 2 underwent revascularization proce-
dures. In comparison, 85 of the 576 patients (16%)
without LGE underwent subsequent assessment for the
presence of obstructive coronary disease (p < 0.001). We
conclude that, although limited by veriﬁcation bias, an
ischemic pattern of LGE was strongly associated with
signiﬁcant angiographic coronary stenosis and subsequent
coronary revascularization.Mortality. There were 68 deaths over amedian of 42months
of follow-up. The mortality rate of the whole cohort was 2.9%
per patient-year. There were 46 deaths among 582 patients
without LGE (2.3% mortality rate per patient-year),
compared with 22 deaths among 88 patients with LGE
(8.1% mortality rate per patient-year).
Univariate and multivariate associations with mortality.
We tested the associations with mortality among 3 cohorts:
all patients, patients without evidence of MI by clinical
history or ECG, and patients without evidence of MI
by clinical history, ECG, or LGE imaging. Among the
entire cohort of all patients, there were 78 deaths. On
univariate analysis among all patients (Table 3), age (HR:
1.05; 95% conﬁdence interval [CI]: 1.02 to 1.07; chi-square
likelihood ratio [LRc2]: 14.9; p ¼ 0.0001), diabetes (HR:
2.07; 95% CI: 1.23 to 3.50; LRc2: 7.56; p ¼ 0.006),
hypertension (HR: 1.72; 95% CI: 1.10 to 2.71; LRc2: 5.55;
p ¼ 0.02), heart failure (HR: 1.76; 95% CI: 1.17 to 2.80;
LRc2: 5.92; p ¼ 0.01), left atrial dimension (HR: 1.04;
95% CI: 1.01 to 1.08; LRc2: 7.36; p ¼ 0.007), the presence
of LGE (HR: 6.09; 95% CI: 3.88 to 9.55; LRc2: 25.5;
p< 0.0001), and the extent of LGE (HR: 1.17; 95%CI: 1.10
to 1.24; LRc2: 25.8; p < 0.0001) provided the strongest
Table 3
Univariate Analyses for Associations With Mortality
Among All Patients
Variable HR 95% CI LRc2 p Value
Age 1.05 1.02–1.07 14.90 0.0001
Male 0.78 0.47–1.31 0.87 0.35
Duration of AF 1.00 0.99–1.00 0.43 0.51
History of hypertension 1.72 1.10–2.71 5.55 0.02
History of AF ablation 0.80 0.45–1.41 0.59 0.44
History of MI 1.59 0.69–3.67 1.19 0.27
MI on ECG 2.48 1.00–6.17 3.84 0.05
History of diabetes mellitus 2.07 1.23–3.50 7.56 0.006
History of obstructive sleep
apnea
0.98 0.56–1.71 0.03 0.95
History of valvular heart
disease
1.16 0.74–2.80 1.68 0.28
History of heart failure 1.76 1.17–2.80 5.92 0.01
Beta-blockers 1.49 0.90–2.49 2.39 0.12
ACE inhibitors/ARBs 1.58 1.02–2.46 4.10 0.05
Class I antiarrhythmic agents 0.53 0.29–1.02 3.78 0.08
Class III antiarrhythmic
agents
1.51 0.87–2.13 1.91 0.17
Diuretic therapy 1.17 0.67–2.06 1.17 0.57
Statin use 1.73 0.63–2.57 0.51 0.47
Aspirin use 0.75 0.48–1.17 1.59 0.20
Systolic blood pressure 0.99 0.98–1.01 0.86 0.35
Diastolic blood pressure 0.99 0.97–1.01 1.44 0.23
Heart rate 1.01 0.10–1.02 2.56 0.11
BMI 1.04 0.99–1.09 3.12 0.08
Sinus rhythm
(at presentation)
0.90 0.56–1.45 0.19 0.66
AV delay 1.02 0.99–1.01 0.28 0.60
QRS duration 1.01 1.00–1.02 4.02 0.05
QTc duration 1.00 1.00–1.01 0.74 0.39
Echocardiographic
parameters
LV EF 0.99 0.97–1.01 1.51 0.22
Estimated PASP 1.00 0.97–1.04 0.05 0.83
LV diastolic dimension 1.01 0.97–1.06 0.23 0.63
Left atrial dimension 1.04 1.02–1.07 4.38 0.04
CMR imaging
LV EDV 1.00 0.99–1.00 0.02 0.90
LV ESV 1.01 1.00–1.01 1.85 0.17
LV EF 0.98 0.96–1.02 2.99 0.08
LV mass index 1.01 0.99–1.03 0.96 0.39
RV EDV 1.00 0.99–1.00 0.10 0.92
RV ESV 0.99 0.98–1.00 1.27 0.26
RV EF 1.00 0.97–1.03 0.43 0.51
Left atrial dimension 1.04 1.01–1.08 7.36 0.007
LGE
Presence of LGE 6.09 3.88–9.55 25.50 <0.0001
Midmyocardial LGE 5.41 3.28–8.15 18.70 0.0001
Subendocardial LGE 5.92 3.18–8.60 23.20 <0.0001
Extent of LGE 1.17 1.10–1.24 25.80 <0.0001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; LRc2 ¼ chi-square likelihood ratio; other abbreviations
as in Tables 1 and 2.
Figure 2 Survival Probability by Presence or Absence of LGE
Kaplan-Meier curves displaying survival probability in cohorts according to the
presence or absence of late gadolinium enhancement (LGE). Results were
compared using a log-rank test (p < 0.0001).
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2210unadjusted associations with mortality among the entire
cohort. In a multivariate model among all patients, age (HR:
1.04; 95% CI: 1.01 to 1.06; LRc2: 8.81; p ¼ 0.003) and the
extent of LGE provided the strongest adjusted associationswith mortality (HR: 1.16; 95% CI: 1.10 to 1.22; LRc2: 24.5;
p< 0.0001). AKaplan-Meier curve showing the difference in
mortality between all patients according to the presence or
absence of LGE is shown in Figure 2. In a second cohort, we
excluded patients with clinical histories of MI or evidence of
MI by ECG. In that cohort, on univariate analysis, age (HR:
1.05; 95%CI: 1.03 to 1.08; LRc2: 15.2; p¼ 0.0001), diabetes
(HR: 2.39; 95% CI: 1.41 to 4.09; LRc2: 10.3; p ¼ 0.001),
heart failure (HR: 1.78; 95% CI: 1.09 to 2.91; LRc2: 5.37;
p ¼ 0.02), left atrial dimension (HR: 1.04; 95% CI: 1.01 to
1.08; LRc2: 6.47; p¼ 0.01), the presence of LGE (HR: 5.08;
95% CI: 3.08 to 8.36; LRc2: 28.8; p < 0.0001), and the
extent of LGE (HR: 1.15; 95% CI: 1.10 to 1.21; LRc2:
35.6; p < 0.0001) provided the strongest associations with
mortality (Table 4). In a multivariate model, age (HR: 1.05;
95% CI: 1.02 to 1.08; LRc2: 11.1; p¼ 0.009) and the extent
of LGE (HR: 1.15; 95% CI: 1.10 to 1.21; LRc2: 32.5;
p< 0.0001) again provided the strongest adjusted associations
with mortality. A Kaplan-Meier curve showing a signiﬁcant
difference in survival among this cohort, according to the
presence or absence of LGE, is presented in Figure 3. In
the third cohort, we excluded patients with histories
of MI by clinical history, ECG, or an ischemic LGE
pattern on CMR (Table 5). In this third cohort, the extent of
LGE had the strongest unadjusted association with
mortality (HR: 1.24; 95% CI: 1.13 to 1.35; LRc2: 22.4;
p < 0.0001).
Discussion
We aimed to determine the incidence, pattern, and prog-
nostic signiﬁcance of myocardial scar in patients with AF
Table 4
Univariate Analyses for Associations With Mortality in
Patients Without Prior MIs by History or ECG
Variable HR 95% CI LRc2 p Value
Age 1.05 1.03–1.08 15.20 0.0001
Male 0.72 0.42–1.24 1.37 0.24
Duration of AF 1.00 0.99–1.00 0.12 0.73
History of hypertension 1.58 0.98–2.56 3.51 0.06
History of AF ablation 0.89 0.49–1.62 0.15 0.70
History of diabetes mellitus 2.39 1.41–4.09 10.30 0.001
History of obstructive sleep
apnea
1.52 0.97–2.02 2.08 0.18
History of valvular heart
disease
1.51 0.75–3.06 1.36 0.24
History of heart failure 1.78 1.09–2.91 5.37 0.02
History of paroxysmal AF 1.00 0.69–1.46 0.01 0.95
History of persistent AF 1.01 0.69–1.46 0.01 0.98
AF recurrence after PVI 1.39 0.99–1.96 3.67 0.06
Beta-blockers 1.36 0.79–2.32 1.23 0.27
Calcium-channel blockers 1.25 0.71–2.19 0.62 0.43
ACE inhibitors/ARBs 1.22 0.74–2.03 0.60 0.44
Class I antiarrhythmic agents 0.59 0.32–1.08 2.91 0.08
Class III antiarrhythmic
agents
1.27 0.77–2.10 0.85 0.36
Diuretic therapy 0.14 0.61–2.05 0.13 0.71
Statin use 0.83 0.19–1.44 1.57 0.23
Systolic blood pressure 0.99 0.98–1.01 0.73 0.39
Diastolic blood pressure 0.99 0.97–1.01 1.39 0.24
Heart rate 1.01 0.99–1.02 2.32 0.12
BMI 1.04 0.99–1.09 2.65 0.10
Sinus rhythm
(at presentation)
0.86 0.51–1.44 0.33 0.57
AV delay 1.00 0.99–1.01 0.57 0.45
QRS duration 1.01 1.00–1.03 4.03 0.05
QTc duration 1.01 1.00–1.01 2.17 0.14
Echocardiographic
parameters
LV EF 0.99 0.97–1.02 0.03 0.86
Estimated PASP 1.02 0.98–1.05 0.99 0.32
LV diastolic dimension 1.00 0.96–1.06 0.03 0.85
Left atrial dimension 1.03 1.00–1.07 3.15 0.08
CMR parameters
LV EDV 1.00 0.99–1.00 0.09 0.76
LV ESV 1.00 0.99–1.01 0.55 0.46
LV EF 0.99 0.97–1.01 0.66 0.41
LV mass 1.00 0.99–1.01 0.03 0.85
LV mass index 1.00 0.98–1.03 0.23 0.63
RV EDV 0.99 0.99–1.00 0.05 0.83
RV ESV 0.99 0.99–1.00 0.08 0.76
RV EF 0.99 0.96–1.02 0.44 0.50
Left atrial dimension 1.04 1.01–1.08 6.47 0.01
LGE
Presence of LGE 5.08 3.08–8.36 28.80 <0.0001
Midmyocardial LGE 5.91 3.58–11.6 26.70 <0.0001
Subendocardial LGE 3.71 1.95–7.10 15.90 0.0001
Extent of LGE* 1.15 1.10–1.21 35.60 <0.0001
*LGE extent HR is for each 1% absolute increase in LGE volume.
PVI ¼ pulmonary vein isolation; other abbreviations as in Tables 1 to 3.
Figure 3 Survival Probability in Patients Without MI
Kaplan-Meier curves displaying survival probability in a subcohort of patients
without clinical or electrocardiographic histories of myocardial infarction (MI).
Results were compared using a log-rank test (p < 0.0001).
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2211undergoing pulmonary vein isolation. We performed a full
CMR study, including LV LGE imaging, in a large series of
consecutive patients with AF. The principal ﬁndings ofthis study were as follows: 1) the incidence of unanticipated
LV LGE was 13%; 2) there were 2 relatively even patterns of
LV LGE noted in this study, an ischemic pattern and
a nonischemic pattern; and 3) the presence of LV LGE
had a signiﬁcant relationship with mortality, even after
adjusting for key variables such as sex, diabetes, and heart
failure. Similar results were found when we included all
patients with and without prior MIs.
The presence of LV LGE provides strong and comple-
mentary prognostic information in patients with congenital
heart disease (19), MI (14), coronary disease (11), myocar-
ditis (20), aortic stenosis (12), endurance exercise (21),
dilated cardiomyopathy (22), and hypertrophic cardiomy-
opathy (13). However, there are limited data detailing the
presence and prognostic signiﬁcance of LV LGE in patients
with AF. In patients with hypertrophic cardiomyopathy, an
increased volume of LGE was associated with an increased
risk for AF (16,23), but there are no other data supporting
myocardial LGE as a predictor of adverse outcomes in
patients with AF. In patients with AF, there are robust
data showing the associations between age, heart failure,
diabetes, prior smoking, a murmur, and LV hypertrophy
with mortality in patients with AF (24). Although our
results are in a cohort referred for pulmonary vein isolation,
there are consistencies between our work and prior data
in other AF cohorts. Similar to community data (24), we
found in patients referred for ablation that age, diabetes,
and heart failure had unadjusted associations with mortality.
We also provide additive imaging data and found that
imaging provided prognostic information in selected
patients with AF. Data are conﬂicting regarding the role of
conventional imaging indexes and outcomes in patients with
AF (25,26). In the AFFIRM (Atrial Fibrillation Follow-Up
Table 5
Univariate Analyses for Associations With Mortality in
Patients Without Evidence of MI by Clinical History,
ECG, or LGE Imaging
Variable HR 95% CI LRc2 p Value
Age 1.06 1.03–1.09 17.40 <0.0001
Male 0.69 0.40–1.22 1.60 0.21
Duration of AF 0.99 0.99–1.00 0.93 0.33
History of hypertension 1.58 0.94–2.66 2.91 0.09
History of AF ablation 0.76 0.39–1.48 0.64 0.42
History of diabetes mellitus 2.65 1.49–4.69 11.20 0.0008
History of obstructive sleep
apnea
1.56 0.94–2.02 2.28 0.16
History of valvular heart
disease
1.60 0.76–3.39 1.53 0.22
History of heart failure 2.02 1.19–3.41 6.84 0.009
Beta-blockers 1.43 0.81–2.50 1.56 0.21
Calcium-channel blockers 0.60 0.30–1.23 1.92 0.17
ACE inhibitors/ARBs 1.42 0.85–2.40 1.77 0.18
Class I antiarrhythmic
agents
0.57 0.29–1.10 2.80 0.09
Class III antiarrhythmic
agents
1.03 0.61–1.75 0.01 0.89
Diuretic therapy 1.23 0.65–2.32 0.39 0.53
Statin use 1.75 1.02–3.03 4.05 0.04
Systolic blood pressure 0.99 0.98–1.01 0.10 0.74
Diastolic blood pressure 1.01 0.98–1.03 0.81 0.37
Heart rate 1.01 0.99–1.02 2.17 0.14
BMI 1.04 0.99–1.10 2.60 0.11
Sinus rhythm
(at presentation)
0.95 0.55–1.63 0.04 0.85
AV delay 1.00 0.99–1.00 0.11 0.74
QRS duration 1.01 1.00–1.03 4.81 0.03
QTc duration 1.01 0.99–1.02 3.32 0.07
Echocardiographic
parameters
LV EF 0.99 0.97–1.02 0.34 0.56
Estimated PASP 1.03 0.99–1.06 2.51 0.11
LV diastolic dimension 0.99 0.94–1.04 0.24 0.62
Left atrial dimension 1.02 0.98–1.06 0.84 0.36
CMR parameters
LV EDV 1.00 0.99–1.01 0.01 0.95
LV ESV 1.00 0.99–1.01 0.25 0.62
LV EF 1.00 0.98–1.03 0.01 0.96
LV mass 1.00 0.99–1.01 0.13 0.72
LV mass index 1.00 0.98–1.02 0.04 0.85
RV EDV 1.00 0.99–1.01 0.26 0.61
RV ESV 1.00 0.99–1.01 0.26 0.61
RV EF 0.98 0.95–1.01 1.78 0.18
Left atrial dimension 1.02 0.98–1.06 0.65 0.42
LGE
Presence of LGE 4.21 2.18–8.14 18.30 <0.0001
Extent of LGE 1.24 1.13–1.35 22.40 <0.0001
Abbreviations as in Tables 1 to 3.
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2212Investigation of Rhythm Management) study, heart failure
with reduced EF was a stronger predictor of adverse
outcomes compared with heart failure with preserved EF
(25). However, in unselected patients presenting to emer-
gency departments with AF, there was no difference in
outcomes when separated according to EF (26). We alsofound that the presence or absence of heart failure was
a predictor of mortality, while EF was not.
The data on the prognostic value of LGE in a cohort
of patients with AF are complementary and additive to
prior data in patients with both nonischemic and ischemic
patterns of LGE. In this study, these 2 broad, evenly dis-
tributed patterns of myocardial scarring were noted. A
nonischemic pattern of LGE has been shown to be an
independent predictor of mortality in patients with valvular
heart disease (12), in patients with hypertrophic cardiomy-
opathy (27), and in patients with nonischemic cardiomy-
opathy (28). Similarly, LGE in an ischemic pattern has
been shown to be an independent predictor of mortality in
asymptomatic patients (15) and symptomatic patients with
(29) and without a known prior MI (11). Finally, among all
patients referred for CMR scans, combined ischemic and
nonischemic patterns of LGE have been shown to predict
mortality (30). The mechanisms involved in the develop-
ment of LV LGE are not clear but are likely different
according to LGE pattern. The ischemic pattern of LGE is
likely related to silent MI and is similar to data from a large
population-based study of volunteers (15). Speciﬁcally,
Schelbert et al. (15) noted a 17% incidence of unrecognized
MI. We believe that the lower percent of unrecognized MI
in our population is due to a combination of the 20-year age
difference, the percent of patients with diabetes, and base-
line use rates of beneﬁcial medications. However, similar to
our study, Schelbert et al. (15) noted that the presence of an
unrecognized MI was also strongly associated with subse-
quent mortality. We believe that the nonischemic pattern
is likely related to the high percent of patients in our
study with heart failure or reduced EFs (22), as more than
25% of our study group had histories of heart failure or
reduced EFs.
There is signiﬁcant variability in pulmonary vein anatomy,
and imaging is routinely performed before pulmonary vein
isolation in randomized studies of patients undergoing AF
ablation (31,32) and in large clinical registries (6) and is
supported by guidelines (7,9). However, there are limited
data as to whether imaging is required (33), and multiple
modalities exist, each with advantages and disadvantages
(34). The choice of imaging modality usually depends on
local expertise and available equipment and includes
magnetic resonance (10), CT, angiography (35), and ultra-
sound (36). There are comparative data between modali-
ties (37,38), but no study has integrated all imaging
modalities, so a complete comparison is lacking. However,
cardiac CT and CMR imaging provide superior spatial
resolution over ultrasound (39,40) and can also be cor-
egistered with electroanatomical mapping systems (9). Each
has advantages and disadvantages. Cardiac CT is widely
available and may also provide additive information beyond
pulmonary vein anatomy (34); however, CT is associated
with radiation exposure (41), and the presence of incidental
ﬁndings is considerable (42). Magnetic resonance imaging
has less availability, lower spatial resolution, and standard
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2213contraindications to its use (7). Allowing for these, both
CT and CMR imaging provide equivalent anatomical
information (43). In this study, we did not test the ability
of one modality over another to provide anatomical infor-
mation but rather aimed to test whether the accessory
information provided by a CMR study would be clinically
useful. We found that the additive information provided by
a CMR study, the presence of LGE, was an independent
predictor of mortality. The CMR study detected infarct
and noninfarct patterns of LGE, both of which have been
shown to provide additive information in other cohorts
(11,22).
Study limitations. This study should be interpreted within
the context of the design format. There are data detailing
the association between atrial LGE and AF recurrence in
patients with AF (44), but the high-resolution sequence
required is not part of our standard CMR imaging protocol.
We also did not image all patients with AF; we imaged only
patients undergoing pulmonary vein isolation. This likely
represents a different phenotype from all patients with AF.
We wanted to compare this cohort as it relates to all patients
with AF. The AFFIRM study enrolled patients with similar
LV EFs and a similar percent of patients with heart failure
and noted an all-cause mortality rate of 4.7% per year;
however, patients were on average 10 years older than in this
study (45). The Rate Control Versus Electrical Car-
dioversion trial also enrolled patients with similar cardiac
function, a similar proportion of patients with diabetes, and
a higher proportion of patients with heart failure. In that
study, the investigators noted a cardiovascular mortality rate
of 3% per year (46). These data suggest that our cohort has
signiﬁcant similarities with other populations of patients
with AF and that the observed mortality rate is appropriate.
Also, we have no data on whether the presence or absence of
LV LGE inﬂuenced treatment. Although imaging of the
pulmonary veins is part of standard clinical and research
practice, there are no randomized data supporting pre-
ablation imaging on outcomes after ablation of AF. We
recorded the medical therapy at the time of discharge after
pulmonary vein isolation, and the change in patient-speciﬁc
antiarrhythmic therapy over time was not included in this
analysis. Finally, we did not perform a comparison of
available imaging modalities to test their differential effects
on outcomes.
Conclusions
Among a large cohort of patients with AF being referred
for pulmonary vein isolation, we found a 13% incidence
of unanticipated LV LGE. The presence of LV LGE
provided strong prognostic information, with each adjusted
1% increase in LV LGE associated with a 15% increased
risk for death. Many imaging modalities are available for
visualization of the pulmonary vein anatomy before ablation
of AF, and these data support the robust and additive
prognostic information provided by CMR imaging.Acknowledgments
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